Figure 6 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
Year: 2023
Type: other
Abstract: NJT6 detects tumors and lung metastases in vivo by immuno-PET/CT imaging with a high signal-to-noise ratio and low background. A, LM2 cells were injected in the MFP or via the tail vein of NSG mice to induce primary tumors or pulmonary metastases, respectively. Three weeks after tumor initiation, control and tumor-bearing mice were imaged with 64Cu-NJT6 immuno-PET/CT (top) or 18F-FDG PET/CT (bottom), Representative immuno-PET/CT images of maximum-intensity projections of mice imaged at 2 hours post-injection are shown. (i) NSG control mice; signals detected in kidney (K), liver (L), and bladder (B). (ii) Mouse bearing primary tumor; strong signals also detected in primary tumor (T). (iii) Mouse bearing pulmonary metastases; strong signals also detected in lung metastases (LM). (iv) Mouse bearing primary tumor imaged 24 hours after injection with labeled nanobodies; signals still detected in primary tumor. (v) Mouse bearing pulmonary metastases imaged 24 hours post-injection; signals still detected in lung metastases. (vi–viii) Representative images of control mice, mice with primary tumors, and mice with pulmonary metastases imaged with 18F-FDG PET/CT. H, heart. Images are representative of 6 to 7 mice with similar results. B,Ex vivo biodistribution of 64Cu-NJT6, expressed as %ID/g in various organs. N = 3 for all groups. C, Inset, data in B expressed as tissue-to-blood ratios for tumors/MFPs and lungs.
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4380790251